Skip to main content
Back
Watch Compare

Upstream Bio, Inc.

Data quality: 100%
UPB
Nasdaq Manufacturing Chemicals
$10.49
▲ $0.07 (0.67%)
Mkt Cap: 570.87 M
Price
$10.49
Mkt Cap
570.87 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -133.44 M
Capital efficient — spends only 5.78% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)20.42%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-36.44%
Above sector avg (-53.53%)
ROIC-32.12%
Net Margin-5026.03%
Op. Margin-5618.82%

Safety

Debt / Equity
N/A
Current Ratio32.67
Interest CoverageN/A

Valuation

PE (TTM|NTM)
-3.98 | -3.25
Below sector avg (-1.48)
P/B Ratio1.51
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -4.0 -1.5
P/B 1.5 1.6
ROE % -36.4 -53.5
Net Margin % -5026.0 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

7 analysts
Buy
Current
$10.49
+315.4%
Target
$43.57
$15.00
$43.00
$75.00
Forecast
Forward P/E -3.25
Forward EPS -$3.23
Est. Revenue 1.22 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$3.23
-$4.02 – -$2.07
 1.22 M 6
FY2026 -$2.94
-$3.67 – -$2.33
 1.21 M 8

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.70 -$0.78 -11.6%
Q32025 -$0.78 -$0.63 +19.5%
Q22025 -$0.61 -$0.74 -21.2%
Q12025 -$0.48 -$0.51 -5.2%

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
1.06% weight
AVSCX AVSCX
0.08% weight
SHSAX SHSAX
0.08% weight
SHSCX SHSCX
0.08% weight
SHISX SHISX
0.08% weight
VVICX VVICX
0.03% weight
IRCIX IRCIX
0.03% weight
IRSIX IRSIX
0.03% weight
IIRSX IIRSX
0.03% weight
IRSSX IRSSX
0.02% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 20.42% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.85 M Net Income (TTM) -143.44 M
ROE -36.44% ROA -35.34%
Gross Margin N/A Operating Margin -5618.82%
Net Margin -5026.03% Free Cash Flow (TTM) -133.44 M
ROIC -32.12% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 32.67
Interest Coverage N/A Asset Turnover 0.01
Working Capital 377.11 M Tangible Book Value 378.58 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.98 Forward P/E -3.25
P/B Ratio 1.51 P/S Ratio 200.02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 469.57 Fwd Earnings Yield N/A
FCF Yield -23.38%
Market Cap 570.87 M Enterprise Value 498.70 M
Per Share
EPS (Diluted TTM) -2.66 Revenue / Share 0.05
FCF / Share -2.45 OCF / Share -2.45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 5.78% FCF Conversion 93.03%
SBC-Adj. FCF -145.18 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 2.85 M 2.37 M
Net Income -143.44 M -62.81 M
EPS (Diluted) -2.66 -5.58
Gross Profit — —
Operating Income -160.36 M -77.76 M
EBITDA — —
R&D Expenses 136.81 M 62.97 M
SG&A Expenses — —
D&A 188,000.0 89,000.0
Interest Expense — —
Income Tax 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 353.77 M 481.72 M
Total Liabilities 14.00 M 11.87 M
Shareholders' Equity 339.77 M 469.85 M
Total Debt — —
Cash & Equivalents 101.58 M 325.89 M
Current Assets 351.80 M 479.16 M
Current Liabilities 13.45 M 10.74 M